News

April 4, 2014 - NuOrtho Research to be Presented at the World Congress of Osteoarthritis

NuOrtho's latest research will be presented at the Osteoarthritis Research Society International World Congress held April 24-27, 2014.

The research was conducted by a team of US and European researchers to further understand the surface properties of articular cartilage, particularly the role lipids play at lesion sites amenable to treatment with Ceruleau®, NuOrtho’s flagship medical device system.

Source:

Augé WK, Ganguly K, Goodwin PM, Gadomski A, Gehlert RJ. Lipid distribution in human knee and hip articular cartilage correlated to tissue surface roughness and surface active phospholipid layer presence: evidence of cooperative interfacial lipid delivery mechanisms. Osteoarthritis Cartilage 2014; 22: S312-S313.

For more information contact NuOrtho Surgical, Inc. at 617-848-8999.

September 3, 2013 - NuOrtho’s Technology leads to Further Understanding of Articular Cartilage Function

Fall River, MA: September 3, 2013- A recent research publication in a leading physics journal demonstrates that the innovative design of NuOrtho’s flagship arthroscopic surgical device, Ceruleau®, continues to help advance the scientific understanding of articular cartilage function.

The research publication in the journal Acta Physica Polonica B offers insights into the surface function of articular cartilage and how NuOrtho’s physiochemical scalpel works to create a healthy lesion site amenable to reconstituting beneficial surface properties. A multinational team of researchers presents a scientific basis for cartilage surface function that is important for cartilage wound healing and further validates the continued use of NuOrtho’s physiochemical scalpel by surgeons.

Source:

Gadomski A, Beldowski P, Augé WK, Hladyszowski J, Pawlak Z, Urbaniak W. Toward a governing mechanism of nanoscale articular cartilage (physiologic) lubrication: Smoluchowski-type dynamics in amphiphile proton channels. Acta Physica Polonica B 2013; 44(8): 1801-1820.

For more information contact NuOrtho Surgical, Inc. at 617-848-8999.

June 11, 2013 - Two Upcoming Research Publications Highlight NuOrtho’s Advances in Cartilage Science

Fall River, MA: June 11, 2013- Two upcoming research publications in leading scientific journals show that the innovative design of NuOrtho’s flagship arthroscopic surgical device, Ceruleau®, continues to help advance the scientific understanding of cartilage.

The upcoming research publications in the journals Mathematical Biosciences and Cartilage offer insights into the cartilage surface and how NuOrtho’s technology works to create a healthy lesion site amenable to reconstitution of beneficial surface properties. In Mathematical Biosciences, a multinational team of researchers presents a scientific basis for cartilage surface function important for tissue wound healing; and, in Cartilage, basic mechanisms important for wound healing are discussed.

Source:

Gadomski A, Beldowski P, Rubi JM, Urbaniak W, Augé WK, Santamaria-Holek I, Pawlak Z. Some conceptual thoughts toward nanoscale oriented friction in a model of articular cartilage. Mathematical Biosciences 2013; In press.

Augé WK. Translamellar dynamics of the surface active phospholipid layer: proton wave propagation through sphingomyelin raft channels. Cartilage 2013; In press.

For more information contact NuOrtho Surgical, Inc. at 617-848-8999.

February 2, 2013 - NuOrtho’s Chief Clinical Officer is Selected to Serve as a Research Scientist Delegate by the International Cartilage Repair Society

NuOrtho’s Chief Clinical Officer has been selected to serve as a Research Scientist Delegate by the International Cartilage Repair Society. The International Cartilage Repair Society is the main forum for international collaboration in cartilaginous tissue research with its mission to advance science and education in cartilage repair globally. Its upcoming Summit entitled "Osteoarthritis of the Knee and Hip, the final frontier in articular cartilage repair" will be held May 30-June 1, 2013. Only 15 Research Scientists have been selected as Delegates from all applicants worldwide.

NuOrtho is honored by the selection of Dr. Augé as a Delegate to this important Summit. As one of fifteen research scientists chosen worldwide, his selection is a testament to his contributions to articular cartilage repair. The event will increase the visibility of NuOrtho’s flagship product Ceruleau® that enables surgeons to selectively treat damaged or diseased cartilage while preserving the surrounding healthy tissue. By preserving the healthy tissue around a lesion site, this tissue can be enrolled in a healing response toward repair.

Source: www.cartilage.org
For more information contact NuOrtho Surgical, Inc. at 617-848-8999.

November 29, 2012 - Adoption of NuOrtho’s Energy-Based Device Ceruleau continues to Increase

NuOrtho’s flagship arthroscopic surgical device, Ceruleau®, a physiochemical scalpel, which gives surgeons an advanced option for treating damaged articular cartilage, has been approved for use at Park City Medical Center, one of Intermountain HealthCare’s Utah facilities.

Phillip Davidson, MD from the Cartilage Restoration and Joint Resurfacing center at Heiden Davidson Orthopedicsin Park City, Utah commented, “I use the NuOrtho probe to smooth broken and fibrillated cartilage. I find this a very valuable tool in my comprehensive treatment of cartilage lesions. Several patients have reported profound pain relief following chondroplasty with this device.”

“The approval of Ceruleau at Park City Medical Center demonstrates continued adoption of NuOrtho’s technology”, said NuOrtho’s CEO Patrick Janin. “As with any new technology, beneficial patient results are the real key to the success.”

For more information contact Patrick Janin at NuOrtho Surgical, Inc. at (617) 848-8999.

September 24, 2012 - NuOrtho Technology Insights that Integrate over 100 Years of Tissue Research are to be Published

A manuscript written by NuOrtho’s Chief Clinical Officer has been accepted for publication in a leading nanotechnology scientific journal. The manuscript highlights the innovative design of NuOrtho’s flagship arthroscopic surgical device, Ceruleau®, a physiochemical scalpel, which gives surgeons an advanced option for treating damaged articular cartilage. Ceruleau has been developed in order to decrease the disease burden of osteoarthritis.

The publication in the International Journal of Nanosystems discusses how NuOrtho’s technology works to create a healthy lesion site that is amenable to tissue healing by mimicking innate wound healing mechanisms of the body. Interestingly, joints, when viewed as an organ system, function in much the same wound healing manner to combat the development of osteoarthritis.

NuOrtho Surgical CEO Patrick Janin commented, “This publication, while discussing complex scientific topics, displays the remarkable insights of our researchers. As with most complex and highly advanced technologies, it will take some time for industry to fully understand what NuOrtho has accomplished for the treatment of cartilage and osteoarthritis.”

Ceruleau utilizes a highly advanced form of technology called redox magnetohydrodynamics that enables the surgeons to selectively treat damaged or diseased tissue, such as cartilage, while preserving the surrounding healthy tissue. By preserving the healthy tissue around a lesion site, this tissue can be enrolled in a healing response.

Source: Augé WK. Conceptualization of surface-confined nano-assemblies as a biophysical battery circuit during tissue rescue: a bridge to accessing genomic control mechanisms. Int J Nanosystems 2012; 5(1):1-18.

For more information contact Patrick Janin at NuOrtho Surgical, Inc. at (617) 848-8999.

August 7, 2012 - USPTO Issues Important New Patent to NuOrtho Surgical, Inc.

The USPTO has issued a new patent to NuOrtho Surgical. The patent number 8,235,979 is entitled “Interfacing Media Manipulation with Non-Ablation Radiofrequency Energy System and Methods” and extends the foundation of NuOrtho’s energy based device system to include tissue healing responses such as that marked by gene expression. As applied to articular cartilage, tissue healing responses are an important approach to addressing the disease burden of osteoarthritis.

Ceruleau®, NuOrtho’s physiochemical scalpel, utilizes a highly advanced form of technology to enable surgeons the ability to selectively target damaged or diseased tissue while preserving the surrounding healthy tissue. By preserving the healthy tissue around a lesion site, this tissue can be enrolled in a healing response.

For more information contact Patrick Janin at NuOrtho Surgical, Inc. at (617) 848-8999.

April 3, 2012 - Three Recent Publications Highlight NuOrtho’s Technology Advance for the Treatment of Cartilage Damage

Fall River, MA: April 3, 2012 - Three recent publications in leading scientific journals show that the innovative design of NuOrtho’s flagship arthroscopic surgical device, Ceruleau®, gives surgeons an advanced option for treating damaged cartilage.

Ceruleau utilizes an highly advanced form of technology called redox magnetohydrodynamics that enables the surgeons to selectively treat damaged or diseased tissue, such as cartilage, while preserving the surrounding healthy tissue. By preserving the healthy tissue around a lesion site, this tissue can be enrolled in a healing response.

The recent publications in the journals Nano Energy, Cartilage, and Osteoarthritis and Cartilage discuss how NuOrtho’s technology works to create a healthy lesion site that is amenable to tissue healing. In Nano Energy, the scientific basis for how the technology works to create a healthy treatment site is discussed; in Cartilage, a group of researchers verified that beneficial gene expression is induced in cartilage that has been linked to tissue healing; and in Osteoarthritis and Cartilage, the origin of the treatment process as a mimic to the body’s own healing mechanisms is presented.

NuOrtho Surgical CEO Patrick Janin commented, “These publications, along with previous studies in various medical journals, are showing the scientific evidence behind the benefits of Ceruleau. Our company has brought a very complex and highly advanced technology to the medical community in order improve the treatment of cartilage.”

Source:

Augé WK. Inverse Mass Ratio Batteries: an in situ energy source generated from motive proton delivery gradients. Nano Energy 2012; 1(2):309-315.

Ganguly K, McRury ID, Goodwin PM, Morgan RE, Augé WK. Targeted in situ biosynthetic transcriptional activation in native surface level human articular chondrocytes during lesion stabilization. Cartilage 2012;3(2):141-155.

Augé WK. Mimicking the respiratory burst myeloperoxidase system of polymorphonuclear neutrophil granulocytes to aid the wound healing behaviors of articular cartilage. Osteoarthritis Cartilage 2012;20:S147-S148.

For more information contact Patrick Janin at NuOrtho Surgical, Inc. at 617-848-8999.

February 8, 2012 - Medical Device Industry Veteran Named as NuOrtho Surgical CEO

FALL RIVER, MA. February 8, 2012 — NuOrtho Surgical Inc., a developer of innovative surgical instruments, announced today that Patrick Janin has been appointed as the new President and Chief Executive Officer of the company.

Mr. Janin is a seasoned executive with a 20-year track record of building innovative products and companies. Mr. Janin was CEO and President of Future Medical Systems (FMS) and Advanced Bio Materials SA , where he led the development of an innovative arthroscopic fluid management and motorized resection system that captured a leading market share in Europe. He then led the sale of the company and the successful integration of the business into Johnson & Johnson’s DePuy Mitek. Janin holds a MBA from Georgetown University - The McDonough School of Business and a BA in International Business from Skidmore College.

NuOrtho is currently commercializing Ceruleau®, a cutting-edge surgical device used to remove damaged cartilage in order to rescue the surrounding healthy tissue and promote long term patient benefits. Ceruleau® is designed with an innovative protective electrode tip that allows it to work differently than other energy based products used during arthroscopic surgery. Ceruleau® uses an Engineered Irrigant within its fluid management system to precisely target damaged tissue.

September 9, 2011 - NuOrtho Surgical Announces New Product Release to Market

Fall River, MA: September 9, 2011 – NuOrtho Surgical Inc., a developer of innovative surgical instruments, has released to market their latest surgical probe offering in the Ceruleau® family of products. The new medical device from NuOrtho expands Ceruleau’s use to both Valleylab and ConMed® electrosurgical generators, effectively doubling the product line’s potential market and covering the vast majority of installed US operating rooms.

Ceruleau probes are used by surgeons during arthroscopic surgery to debride diseased or damaged cartilage while preserving the healthy tissue by use of an innovative and proprietary electrode tip design. A unique NuOrtho market advantage is that Ceruleau is powered by previously installed electrosurgical generators and doesn’t require a dedicated capital investment.

"Ceruleau’s precision technology offers surgeons the unique ability to achieve successful treatment for articular cartilage lesions, while preserving healthy tissue." said NuOrtho Surgical Chief Development Officer, Roy Morgan. "With the addition of the Ceruleau for ConMed generators, the product can be used in almost all US operating rooms and surgical suites with the previously installed generators. This improvement will accelerate the market share growth Ceruleau is already experiencing in the field."

NuOrtho has already received orders for the new Ceruleau device and is currently shipping to meet the demand.

April 8, 2011 - Innovative Surgical Device to Rescue Cartilage is used for first time in New Jersey

Fall River, MA: April 8, 2011 – A new, innovative arthroscopic surgical device was successfully used recently in a New Jersey knee surgery to treat articular cartilage lesions and rescue the surrounding healthy tissue. The surgery, performed by Merrick Wetzler, MD at Summit Surgical Center in Voorhees, was the first surgery in the New Jersey utilizing the new product branded Ceruleau™. The Surgical Center reported that the patient was doing well and already resuming normal activities.

The new is designed to aid surgeons during arthroscopic surgery to remove diseased or damaged cartilage while rescuing the healthy tissue to help promote long term healing. The device, called Ceruleau™ and manufactured by NuOrtho Surgical Inc., was recently approved by the U.S. Food & Drug Administration. Ceruleau is built with an innovative protective electrode tip that allows it to work differently than other products used for this surgery. The tip and its mechanism are key to resecting the diseased tissue while at the same time, helping to preserve a patient's healthy tissue.

Dr.Wetzler, who performed the first and several subsequent surgeries at Summit Surgery Center, said knee pain caused by "rough," or fibrillated, cartilage is very common and have been treated with various surgical instruments. However, many times these cartilage lesions are left untreated because surgeons are concerned about damaging the healthy tissue surrounding the diseased tissue. Ceruleau™ was developed to allow for the removal of cartilage lesions and prevent any damage to the surrounding healthy tissue.

"The Ceruleau device is unique,” Dr. Wetzler said. "The research studies associated with this product — and now the surgical results — give us compelling evidence that we have a new treatment option for articular cartilage disease that." “Ceruleau targets just the diseased cartilage and rescues the healthy tissue with a physiochemical scalpel that operates with great precision.” The Doctor added: “This new technique is particularly beneficial in the treatment of patients with osteoarthritis (fibrillated cartilage); one of the most common forms of knee arthritis that progress with time.”

NuOrtho’s CEO, Jeff Morrill shared these comments: "We know that surgeons like Dr. Wetzler want the best outcomes for their patients using the most advanced technology and techniques available. Ceruleau’s precision technology offers the surgeon an opportunity to achieve successful, treatment and even early intervention for articular cartilage lesions, while rescuing healthy tissue."

April 4, 2011 - NuOrtho Surgical Appoints Greg Rainey to Board

FALL RIVER, MA. April 4 2011 — NuOrtho Surgical, Inc. announced today the appointment of Gregory Rainey to its board of directors. Mr. Rainey has extensive experience in the medical device industry in various senior executive roles. Since 2004, Mr. Rainey has been the president of CCI Performance Group, LLC, which provides consulting services for healthcare companies.

NuOrtho Surgical CEO, Jeff Morrill stated: "Greg Rainey is a well respected medical device executive. Under his leadership as Vice President of Sales, the Stryker Orthopedics Division nearly doubled sales to over $1 billion dollars in just 4 years. For the last 7 years he has been helping companies similar to ours establish strong commercial success. And Greg also brings valuable board experience to NuOrtho from his director roles at RTI Biologics and CAS Medical. We believe his considerable commercial experience and his success in creating value for patients, physicians and shareholders will be extremely helpful to NuOrtho as we continue to expand the commercialization of our soft tissue platform”.

Mr. Rainey commented: "I look forward to working with a very talented management team at NuOrtho as they are launching their first product, Ceruleau, for better healthcare treatment of cartilage in the knee for the orthopedic market. It’s exciting to be joining such an innovative company that has tremendous potential for improving orthopedic outcomes for patients and physicians.”

In addition to his role as President of CCI Performance Group, Mr. Rainey is a member of the Board of Directors at RTI Biologics, Inc, as well as a Board member at CAS Medical Systems, Inc. Mr. Rainey spent the majority of his career at Stryker Corporation where his roles included Vice President of Sales and member of the Executive Committee of Stryker’s $1.2 billion orthopedic division

March 30, 2011 - Innovative Surgical Device to be featured at World Science Congress

Fall River, MA: March 30, 2011 – Nine Nobel Laureates will be among the top science leaders at the World DNA and Genome Day Conference and the World Congress of Marine Biotechnology as a new physiochemical scalpel is showcased as a tool in the battle against arthritis.

Dr. Wayne Augé, Chief Clinical Officer of NuOrtho Surgical, Inc., has been invited to Chair the Human Genetics and Disease section of the World DNA and Genome Day Conference and will give a presentation titled: Addressing the Large World-wide Disease Burden of Osteoarthritis through Targeted Induction of Biosynthetic Gene Expression: Early Intervention Engineered to Reverse Articular Cartilage Lesions. He has also been invited to discuss his research at the World Congress of Marine Biotechnology and will give a presentation titled: The intimate relationships between tissue surface barriers and their saline environments create a therapeutic substrate for the surgical rescue of diseased tissue: a molecular energy conversion loop designed for surgical work.

Among the items to be presented is a new surgical device designed to aid surgeons during arthroscopic surgery to remove diseased or damaged cartilage while rescuing the healthy tissue to help promote long term healing. The device, called Ceruleau®, is manufactured by NuOrtho Surgical Inc., and was recently approved by the U.S. Food & Drug Administration. Ceruleau is built with an innovative protective electrode tip that allows it to work differently than other products used for cartilage surgery. The tip and its mechanism are key to resecting the diseased tissue while helping to preserve a patient's healthy tissue.

The World DNA and Genome Day Conference and the World Congress of Marine Biotechnology will be held in Dalian, China and will cover extensive topics of modern life science and industrial biotechnology. The conference includes the integration of 6 concurrent world-class congresses in one week and lectures by 9 Nobel Prize Laureates. Industry leaders from academia, government, and health care companies from all over the world will be in attendance at the conference.

“We are honored by the invitation from the organizers of these prestigious events to discuss the importance of rescuing healthy tissue during arthroscopic surgery” said NuOrtho Surgical CEO, Jeff Morrill. “Ceruleau’s precision technology offers the surgeon an opportunity to achieve successful early intervention for articular cartilage lesions while rescuing healthy tissue. The advanced surgical results obtained by surgeons using Ceruleau show that there is a new treatment option for articular cartilage disease.

The World DNA and Genome Day Conference and the World Congress of Marine Biotechnology will run from April 25-29th. Dr Auge’s presentations will be on April 26th and April 27th at the Dalian World Expo Center – Dalian, China. For more information on the conference and the world congresses, visit: http://www.dnaday.com/ and http://www.bitlifesciences.com/wcmb2011/

NuOrtho Surgical is focused on surgical instruments to enable Tissue Preservation in the orthopedic arena to improve patient outcomes. The technology leverages a low level Radio Frequency energy to restore mobility in patients by preserving healthy tissue in both soft and hard tissue procedures. NuOrtho has three primary product platforms for preserving healthy Tissue to sustain long-term mobility in our busy lives, particularly for Baby Boomers. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. More information can be found at http://www.nuorthosurgical.com

Please contact NuOrtho Surgical for copies of abstracts of the presentations.

Please contact Chris Heye, cheye@nuorthosurgical.com, with any questions.

December 29, 2010 - Massachusetts Life Sciences Center Approves Tax Incentives for Fall River-based NuOrtho Surgical, Inc.

Waltham, MA – The Massachusetts Life Sciences Center has authorized Fall River-based NuOrtho Surgical, Inc. to receive state tax incentives totaling $573,000. In return the company has committed to the creation of 25 new jobs in 2011. The Center has approved a total of $23.9 million in 2010 tax incentives to encourage growth at 30 life sciences companies. The recipient companies have committed to creating nearly 1000 new jobs in 2011.

The Life Sciences Tax Incentive Program, established in 2008 as part of the state’s ten-year, $1 billion Life Sciences Initiative, authorizes up to $25 million in tax incentives each year for companies engaged in life sciences research and development, commercialization, and manufacturing. The primary goal of the program is to incentivize life sciences companies to create new sustained jobs in Massachusetts.

The Life Sciences Act provides for nine different incentives, which address the significant capital expenditures associated with the life sciences R&D cycle and the high costs of translating research into commercially viable products. This is the second year that incentives have been provided under the program.

"We are thrilled that the Life Sciences Center has selected NuOrtho Surgical for this award,” said Chris Heye, Chief Operating Officer for NuOrtho Surgical, Inc. “We started our company here in Fall River to help orthopedic surgeons battle major disease states like osteoarthritis. We are deeply honored that the Life Sciences Center recognizes our science and product potential. The tax incentive award comes at a very important time for our company as we look to rapidly expand and add jobs to help further accelerate our growth."

“The Life Sciences Initiative is all about jobs and better health,” said Governor Deval Patrick. “These incentives help us build a stronger foundation for our economy and for healing for years to come.”

“These tax incentives are providing a solid return on our state’s investment in both the short and long term, with this year’s round of recipients committing to create nearly 1,000 new jobs during the coming year,” said Dr. Susan Windham-Bannister, President & CEO of the Massachusetts Life Sciences Center. “We are utilizing these incentives to encourage the creation of jobs in sectors where Massachusetts is a global leader, and where jobs typically pay more than the average salary in Massachusetts. This tax incentive program is already working to stimulate our economy, while holding the companies involved accountable for their job creation commitments.”

“The companies that will receive these incentives are adding jobs in a cutting-edge industry that is a strength for Massachusetts,” said Massachusetts Administration and Finance Secretary Jay Gonzalez, Co-chairman of the Center’s Board of Directors. “The Governor’s Life Sciences initiative not only offers hope to those waiting for cures for diseases, but to the Commonwealth as a whole as we look to grow our economy and lay the foundation for long-term economic competitiveness and success.”

“These investments continue to position the Commonwealth for long term sustainable job growth and further support our place as a global leader in the innovation economy,” said Massachusetts Secretary of Housing & Economic Development Gregory Bialecki, Co-chairman of the Center’s Board of Directors.

“Great to see the life sciences industry grow in the Southcoast region,” said State Representative Michael Rodrigues (D-Westport). “With the addition of 25 new jobs at NuOrtho Surgical, it is exciting to see a 21st century economy take shape here in Fall River. To continue building a lasting foundation, leading to expanded job opportunities for our residents, we must continue to emphasize economic growth driven by the life sciences and tech-related sectors.”

The Tax Incentive Program is jointly administered by the Center and the Massachusetts Department of Revenue (DOR), which will oversee the technical administration of the incentives. Jobs that are created must be maintained for at least five years. The Tax Incentive Program mandates that awarded companies submit reports and respond to inquiries by the Center and DOR regarding employment figures. If a company receiving a tax incentive under the program does not meet and maintain their job creation commitment, the credit can be “clawed back” (recovered) by DOR, requiring that the company pay back all or a portion of the tax incentives they’ve received.

About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a ten-year, $1 billion initiative that was signed into law in June of 2008. The Center’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties between sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.

About the Life Sciences Tax Incentive Program
The Life Sciences Initiative authorizes the Center to award up to $25 million in tax incentives each year. Applicants are generally companies that have transitioned or are transitioning from pure life sciences research and development (“R&D”) to commercialization and manufacturing. The Center recognizes that many companies struggle to address the significant capital investment associated with the long life sciences R&D cycle and the high cost of translating research into a commercially viable product. This solicitation is designed to help sustain these companies through a critical stage of development and to leverage additional sources of capital to bring cutting edge innovation to the marketplace.

December 24, 2010 - New Study Shows how Unique Surgical Device Design is Key to Preserving Healthy Tissue

Fall River, MA: December 24, 2010- A recent study in a leading scientific journal shows that the innovative design of a newly released arthroscopic surgical device, called Ceruleau™, gives surgeons an advanced option for treating tissue.

The new device from NuOrtho Surgical Inc, utilizes a distinctive protective housing at the tip of the surgical instrument that allows the Surgeon to selectively treat damaged or diseased tissue, such as cartilage, while preserving the surrounding healthy tissue. Other Surgical probes do not have this protective housing and consequently have been shown to kill healthy tissue around the treatment site.

The study, published in the most recent volume of WATER, a Multidisciplinary Research Journal, describes how Ceruleau’s™ non-ablation radio frequency energy and its patented design work during surgery. The study further illustrates how the device uses a primary reaction zone within its ceramic housing to modify arthroscopic fluid and to protect tissue from direct electrode-to-tissue contact.

NuOrtho Surgical CEO Jeff Morrill commented, “This Water Journal study, along with previous studies in various medical publications, is showing the scientific evidence behind the benefits of Ceruleau™. Our company was started with the belief that preserving healthy tissue is a critical foundation for improving orthopedic procedures for surgeons, hospitals, and patients. We have been thrilled with the medical community's reaction to our first product Ceruleau™.

Source: McRury ID, Morgan RE, Augé II WK. The Manipulation of Water with Non-Abla¬tion Radiofrequency Energy: A Repetitive Molecular Energy Conversion Loop under Non-Ionizing Electromagnetic Forces. WATER: A Multidisciplinary Research Journal Volume 2, 2010

For more information contact: Chris Heye/NuOrtho at 617-848-8999

December 15, 2010 - New device for knee surgery used for first time at Southcoast Hospitals

St. Luke's Hospital orthopedic surgeon Jeremy B. Stern, MD, is first in U.S. to use device made by Fall River firm

NEW BEDFORD, Mass. — Southcoast Hospitals Group announced today that orthopedic surgeon Jeremy B. Stern, MD, recently became the first surgeon in the U.S. to use a new surgical device for a common type of knee surgery at its St. Luke's site in New Bedford. The device, created by a Fall River firm, is designed to aid surgeons during arthoscopic surgery to remove diseased or damaged cartilage while preserving the healthy tissue to help promote long term healing.

The device, called Ceruleau™ and manufactured by NuOrtho Surgical Inc. in Fall River, was approved by the U.S. Food & Drug Administration earlier this year. Ceruleau is built with an innovative protective electrode tip that allows it to work differently than other products used for this surgery. The tip and its mechanism are key to helping preserve a patient's healthy tissue. This is the first surgery using this device to take place in the U.S.

Dr. Stern, who performed the surgery on November 15 at St. Luke's Hospital, said knee pain caused by "rough," or fibrillated, cartilage is very common and usually treated with a number of techniques to restore the area back to a smooth surface to eliminate pain.

"The Ceruleau device fine tunes the excellent surgery we were already performing," Dr. Stern said. "The research studies associated with this product — and now the surgical results — give us compelling evidence that we have a new treatment option for articular cartilage disease."

Ceruleau is an electrosurgical wand-like device that smoothes the cartilage by selectively targeting diseased tissue to preserve as much healthy tissue as possible without hurting the surrounding tissue. The design of the device — a protected electrode to avoid electrode-to-tissue contact in combination with, a low radio frequency energy — allows for localized treatment of damaged cartilage tissue while sparing healthy cartilage.

This new technique is particularly beneficial in the treatment of patients with osteoarthritis (fibrillated cartilage), one of the most common forms of knee arthritis that progresses with time, Dr. Stern said.

"We know that surgeons like Dr. Jeremy Stern want the best outcomes for their patients using the most advanced technology and techniques available," said Jeffrey W. Morrill, Chief Executive Officer of NuOrtho Surgical Inc. "Ceruleau and the non-ablative radiofrequency technology offers the surgeon an opportunity to achieve successful, early intervention for articular cartilage lesions, while preserving healthy tissue."

September 27, 2010 - Battle Against Articular Cartilage Disease

Fall River, MA: September 27, 2010- New, ground breaking research shows promising advancements in the battle against articular cartilage disease. A new study, presented this week at the 9th World Congress of the International Cartilage Repair Society conference in Barcelona, Spain revealed that chondron density can increase in response to non-ablation radiofrequency energy. Articular cartilage disease is a large and growing problem as the US population ages. Orthopedic surgeons are able to visibly see the disease progressing but have had limited options to stop the loss of chondron density.

This new research, presented to a gathering of many of the world's top cartilage researchers and orthopedic surgeons, examined how non-ablative radiofrequency energy can preferentially increase articular cartilage Superficial Zone live chondron density. Resetting functional chondron density patterns may have the potential to create a more chondro-supportive environment for articular cartilage as it inherently responds to disease.

Dr. Jack Farr, a leading orthopedic surgeon out of Indianapolis stated, “The research presented at the conference shows a compelling case for a new treatment option we now have for articular cartilage disease. This non-ablative technology now allows us to selectively target and remove damaged tissue without causing necrosis in the contiguous cartilage tissue surrounding the lesion. This is an important step forward.”

NuOrtho Surgical, Inc is the medical device company that developed and sells the new non-ablative RF energy surgical probe used in the study. NuOrtho CEO, Jeff Morrill, released the following statement, "Ceruleau® is the product used in the study to achieve these promising results. The opportunity to achieve successful early surgical intervention for articular cartilage lesions rather than waiting for full-thickness lesions to develop has recently been made possible with the advent of non-ablation radiofrequency technology and Ceruleau®. With our recent FDA clearance for Ceruleau®, we are excited to bring this surgical tool to orthopedic surgeons."

Additional information on the ICRS presentation as well as further details of the study can be found at: http://posters.webges.com/get/pdf/icrs2010/3754/

NuOrtho Surgical is focused on surgical instruments to enable Tissue Preservation℠ in the orthopedic arena to improve patient outcomes. The technology leverages a low level Radio Frequency energy to restore mobility in patients by preserving healthy tissue in both soft and hard tissue procedures. NuOrtho has three primary product platforms for preserving healthy Tissue to sustain long-term mobility in our busy lives, particularly for Baby Boomers. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion.


August 15, 2010 - Two Recent Studies Offer New Cartilage Lesion Insights

Fall River, MA (PRWEB) August 15, 2010 - NuOrtho Surgical, Inc. today announces that the findings of two separate studies discussing early surgical intervention for the articular cartilage damage of osteoarthritis.

The studies demonstrate that damaged cartilage retains viable cartilage cells at stages of the degeneration process from normal to surface fibrillation. The studies also confirm many previous studies that current treatments using thermal and plasma ablation devices can caused additional damage to articular cartilage. The studies were performed at the Center for Integrated Nanotechnologies, Los Alamos National Laboratory, Los Alamos, New Mexico, in conjunction with Physicians Medical Center of Santa Fe, Santa Fe, New Mexico.

NuOrtho's Ceruleau™ probe was tested due the new non-ablation approach to tissue preservation that it represents. The current ablation radiofrequency devices tested, including Smith and Nephew's Glider® probe and Arthrocare's Paragon® probe, are designed for ablation of tissue and therefore can cause collateral damage. Ceruleau allows for targeted removal of diseased tissue without causing the collateral damage of ablation devices that has been a concern to surgeons. The study, titled “Histopomorphic Evaluation of Radiofrequency Mediated Debridement Chondroplasty”, states that “The morphologic and histologic treatment results created by Ceruleau are vastly superior to those of other debridement chondroplasty techniques.” and “The low-level energy delivery is configured to modify/precondition diseased cartilage to a state amenable to a safe and effective gentle mechanical débridement.”

NuOrtho Surgical is focused on surgical instruments to enable Tissue Preservation℠ in the Orthopedic arena to improve patient outcomes. The technology leverages a low level Radio Frequency energy to restore mobility in patients by preserving healthy tissue in both soft and hard tissue procedures. NuOrtho has three primary product platforms for preserving healthy Tissue to sustain long-term mobility in our busy lives, particularly for Baby Boomers. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion

Source: Ganguly K, McRury ID, Goodwin PM, Morgan RE, Augé WK. Histopomorphic evaluation of radiofrequency mediated débridement chondroplasty. Open Orthop J 2010; 4:211-220.

Ganguly K, McRury ID, Goodwin PM, Morgan RE, Augé WK. Native chondrocyte viability during cartilage lesion progression: normal to surface fibrillation. Cartilage; July 22, 2010 as doi:10.1177/1947603510373918

For more information contact: Chris Heye/NuOrtho at 617-848-8999


July 6, 2010 - NuOrtho Surgical receives FDA 510(k) Clearance

Fall River, MA, July 6, 2010, NuOrtho Surgical, Inc., a developer of leading edge surgical instruments, received 510(k) clearance from the Food and Drug Administration clearance to market its Ceruleau™ surgical probe in the United States.

Ceruleau™, is a 3.5 mm arthroscopic radio frequency (RF) electrosurgical probe made for the treatment of soft tissues, particularly fibrillated articular cartilage. This novel electrosurgical device is designed to aid the surgeon by selectively targeting diseased cartilage tissue during procedures intent to restore smooth chondral surfaces. Studies have demonstrated that its design, which combines low RF energy delivery with a protected electrode (to avoid electrode-to-tissue contact), allows for localized treatment of damaged/fibrillated cartilage tissue while avoiding harm to healthy cartilage.

"This 510(k) clearance is an important step towards advancing our technology and the Tissue Preservation™ platform" said Jeff Morrill, CEO of NuOrtho Surgical. "We repeatedly hear that surgeons want to do everything they can to maximize the preservation of healthy tissue during surgical procedures. Ceruleau™ helps deliver this need for surgeons and patients. This is the first product of many we are developing in support of our Tissue Preservation™ platform".

Manufacturing of Ceruleau™ is underway and NuOrtho Surgical is finalizing launch plans for the new product. NuOrtho has signed agreements with a number of leading medical device distributors around the country to help build rapid market penetration.

NuOrtho Surgical Inc., is currently focused on the design and manufacture of surgical devices that enable Tissue Preservation™ to improve patient outcomes in the orthopedic arena. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion, however to date only the Ceruleau™, product has been cleared to market. In addition to the patents held for Ceruleau™, the company has numerous other patents, providing significant business opportunities.


June, 2010 - NuOrtho Surgical named as one of top 50 companies to watch in 2010

MDDI - Top 50 companies to watch 2010 FALL RIVER, MA (June 2010) – NuOrtho Surgical, Inc has been recognized by Medical Device and Diagnostic Industry (MD+DI) magazine as one of the top 50 companies to watch for in the medical device industry in 2010. NuOrtho Surgical is focused on surgical instruments that enable Tissue Preservation℠ in the Orthopedic arena to improve patient outcomes.

MD+DI went through a meticulous process to analyze all possible information on the nominated companies to select the final Top 50 companies. In the recent June 2010 publication, the magazine writes "The challenge for MD+DI editors was to identify not only those companies that have achieved success, but also to find those manufacturers with the potential to revolutionize care practices".

CEO of NuOrtho Surgical, Jeffrey Morrill, commented "We are honored that MD+DI recognizes NuOrtho Surgical as one of the companies that can revolutionize care practices. As the population ages, there is a growing need to sustain long-term mobility, particularly among baby boomers. The future is bright for innovative products like ours that have a clear point of difference and benefits.

NuOrtho has completed 510K FDA regulatory filing and is awaiting clearance for Ceruleau™ an orthopedic probe which is designed to remove damaged cartilage and preserve healthy tissue during surgery. Mr Morrill added "MD+DI reported that they often selected companies that 'often boasted ground breaking technologies.'. We believe Ceruleau™ and other products in our portfolio have enormous potential and it is rewarding for the Company to be recognized in this way".

MD+DI solicited nominations from readers, its Editorial Advisory Board and Reader Board, and industry observers, and analyzed nominee information before producing the list.

NuOrtho Surgical is focused on the manufacture of surgical instruments that enable Tissue Preservation™ in the orthopedic arena to improve patient outcomes. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. NuOrtho’s first product launch will be Ceruleau™, a revolutionary product for soft tissue treatment in knee procedures for cartilage. The company has a growing patent portfolio, as they added another one recently, providing significant business opportunities.


May, 2010 - NuOrtho Surgical names Eric E. Ray Director of Sales - USA

FALL RIVER, MA (May 2010) – Jeffrey Morrill, CEO of NuOrtho Surgical, Inc. of Fall River, Massachusetts, is pleased to announce that Eric E. Ray has joined the company as Director of Sales for the United States.

“Eric is a great addition to our team. As a veteran medical device sales and marketing executive with 14 years of orthopedic device knowledge, he has proven experience in launching new products and growing sales at both start-up firms and large corporations. Eric’s talents, leadership and dedication will provide the qualities needed to organize our sales, marketing, professional education and customer service efforts, something he has done before in his career, and we expect him to perform at a high level in his role for NuOrtho Surgical, Inc.,” stated Morrill.

Mr. Ray gained much of his experience at Johnson & Johnson’s Depuy, a $13 billion medical device division, where he served in various sales, management and marketing roles for eight years. While at DePuy, Mr. Ray managed more than $50 million in products and commercially launched several products overseas. He also served as National Sales & Marketing Manager for DePuy Mitek in Australia, providing the initiatives for change and capitalization on various sports medicine and joint ventures.

Mr. Ray has brought a great network of industry sales contacts to NuOrtho and has already begun signing and entering into contract negotiations with a variety of strategic key agent groups throughout the country. “Eric has made an immediate impact in executing our go-to-market plans,” stated Morrill.

“NuOrtho’s unique product line provides an opportunity to improve the surgical outcome for surgeons and the active Baby Boomer generation. NuOrtho is a great company, and it will be a pleasure to lead their sales efforts,” stated Ray.

NuOrtho Surgical is focused on the manufacture of surgical instruments that enable Tissue Preservation™ in the orthopedic arena to improve patient outcomes. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. NuOrtho’s first product launch will be Ceruleau™, a revolutionary product for soft tissue treatment in knee procedures for cartilage. The company has a growing patent portfolio, as they added another one recently, providing significant business opportunities.


March 26, 2010 - NuOrtho Surgical working with regulatory expert for FDA filing

Fall River, MA, March 26, 2010 - NuOrtho Surgical, Inc., a developer of leading edge surgical instruments, announced it has retained the services of RA/QA International L.L.C. for assistance in completing the 510K FDA regulatory filing for the Ceruleau™ orthopedic probe. RA/QA, headed by Martin Leighton, has been assisting companies with domestic and international regulatory submissions since 1996.

"Martin and his firm bring a wealth of knowledge and experience to us as we finalize our regulatory submission for our product Ceruleau™ which is designed to remove damaged cartilage and preserve healthy tissue during surgery." said NuOrtho CEO, Jeff Morrill. "This is the first product of many we are developing for our Tissue Preservation™ platform and it was important for us to partner with one of the best in completing our FDA submission. RA/QA provides another quality regulatory resource to our team and they will help ensure that we provide the FDA with a thorough and robust filing."

RA/QA's Martin Leighton commented "I am pleased to be working with NuOrtho on this submission. The more I learned about their Tissue Preservation™ platform and their products, the more involved I wanted to be with this innovative company."

Martin Leighton, Principal of RA/QA International is a Bio-Medical Engineer and was formerly Executive Director of Operations and Strategic Business Development for the US Medical Division of TÜV Product Service, a Division of TÜV America, Inc. Martin has worked with companies such as Agilent Technologies (now Phillips Medical, formerly HP Medical Products), Chiron Vision, Alcon, Bausch & Lomb, Teleflex Medical/Arrow Int., Baxter, Colorado MEDtech, Genzyme, Hill-Rom, Johnson & Johnson, Medtronic, MedSource, Siemens, Smith + Nephew, Respironics, TYCO (Sherwood, Davis+Geck, USSC), C. R. Bard, Bristol-Myers Squibb Medical Imaging and many more.

RA/QA International provides hands-on consulting services to the medical devices industry for regulatory submissions, compliance and quality management systems. Recently RA/QA International, L.L.C. has also added ISO 14644 clean room certification services to its product offering Martin was trained at the FDA’s Staff College for “Pre-market Notification 510(k) Review for Third Party Organizations” and “Quality System Regulation (QSR)-Design Controls Assessments.”

NuOrtho Surgical is focused on the manufacture of surgical instruments that enable Tissue Preservation™ in the orthopedic arena to improve patient outcomes. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. NuOrtho’s first product launch will be Ceruleau™, a revolutionary product for soft tissue treatment in knee procedures for cartilage. The company has nine patents providing significant business opportunities.


March 19, 2010 - NuOrtho Surgical Names Darik Volpa to Board of Directors

Jeffrey Morrill, CEO of NuOrtho Surgical, Inc. of Fall River, Massachusetts, is pleased to announce that Darik Volpa, CEO of Understand.com, has joined its Board of Directors. Mr. Volpa has led the privately held company to seven straight years of record sales growth.

Fall River, MA March 19, 2010 - Jeffrey Morrill, CEO of NuOrtho Surgical, Inc. of Fall River, Massachusetts, is pleased to announce that Darik Volpa, CEO of Understand.com, has joined its Board of Directors.

“Darik Volpa is a great addition to our Board of Directors. As the founder and CEO of Understand.com, a global provider of medical content that helps healthcare professionals and companies better communicate diseases, conditions, and procedures to patients using 3D animation, Darik is well suited for NuOrtho,” stated Morrill.

Mr. Volpa gained much of his experience at Stryker Corporation, a $6 billion medical device company, where he served in various sales and marketing roles for nine years. While at Stryker, Mr. Volpa managed more than $50 million in products and commercially launched the first synthetically engineered bone morphogenetic protein (BMP).

Mr. Volpa was named the 2007 Innovator of the Year by The Business Report of Northern Nevada. In 2006, Mr. Volpa was awarded "Best of Show" at the Silver & Gold Venture Capital Conference representing Understand.com. In 2009, the company was a finalist for “Best Places to Work” in Northern Nevada by the Economic Development Authority of Western Nevada. Mr. Volpa was the recipient of the Reno Gazette Journal “20 Under 40” award, and he was named a “20/20 Business Visionary” by Nevada Business Magazine.

Understand.com has educated more than 5,000,000 patients and has thousands of clients licensing content globally. Mr. Volpa has led the privately held company to seven straight years of record sales growth.

NuOrtho Surgical is focused on the manufacture of surgical instruments that enable Tissue Preservation™ in the orthopedic arena to improve patient outcomes. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. NuOrtho’s first product launch will be Ceruleau™, a revolutionary product for soft tissue treatment in knee procedures for cartilage. The company has nine patents providing significant business opportunities. For further information visit www.nuortho.com.


January 25, 2010 - NuOrtho Surgical selects Contract Manufacturing Partner

Fall River, MA, January 25, 2010 - NuOrtho Surgical, Inc., an innovative provider of leading edge surgical instruments today announced it has signed an agreement with Eagle Medical Inc. to provide Contract Manufacturing services. Under the agreement, Eagle Medical will be the manufacturer of NuOrtho's next generation, minimally invasive arthroscopic products.

"We are proud to announce this strategic relationship as we prepare to launch our first product, Ceruleau™ for people with knee pain. We conducted a lengthy search to find the right partner that could meet our high manufacturing expectations. Eagle Medical has a proven track record of working with leading medical device firms that positions them well to scale up around the globe with us", comments NuOrtho Surgical CEO Jeffrey Morrill.

NuOrtho Surgical is focused on surgical instruments to enable Tissue Preservation™ in the Orthopedic arena to improve patient outcomes. The technology leverages a low level Radio Frequency energy to restore mobility in patients by preserving healthy tissue in both soft and hard tissue procedures. NuOrtho has three primary product platforms for preserving healthy Tissue to sustain long-term mobility in our busy lives, particularly for Baby boomers. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. The Bone Fusion technology is a game changer and can fuse bone together, and ultimately has the potential to replace screws and plates that are used in many procedures today.

Eagle Medical, located on the California Central Coast mid-way between San Francisco and Los Angeles, was designed to exceed today's regulatory requirements. Has a modern 10,000 square foot facility has over 1600 square feet of cleanroom and support area designed to provide a high quality environment for assembly and packaging of medical devices.

Eagle Medical's areas of expertise include manufacturing and packaging specialties, process and sterility validation studies, environmental controls, and bringing new products to market. We are well positioned for companies like NuOrtho Surgical and getting their innovative new products ready for FDA clearance and manufacturing “scale up” states Doyle Timmons Eagle Medical President.


January, 2010 - NuOrtho Surgical Names Ian McRury Ph.D. to leadership team as Chief Scientific Officer

FALL RIVER, MA (January 2010) - NuOrtho Surgical, Inc., a medical device firm focused on surgical instruments and procedures to enable Tissue Preservation™ in the orthopedic arena, is pleased to announce the addition of Ian McRury Ph.D. to the senior leadership of the company as Chief Scientific Officer. Dr. McRury brings a wealth of radio frequency knowledge and experience in bringing innovative products to market.

Dr. McRury has been working in the medical devices industry for the past 17 years with industry leaders including Davol, Johnson & Johnson and C.R. Bard. At DePuy Mitek, a division of Johnson & Johnson, he focused on rapid product development and transformational technologies such as the Platform Leader for Tissue Management. He has significant experience developing and launching RF products. During his tenure at Mitek, RF sales increased from $20MM to $75MM.

Dr. McRury holds a B.S. degree from Boston University and a master’s and doctor’s degree from the University of Virginia.

“The addition of Dr. McRury to our company signals another significant step toward building our team to advance the science of Tissue Preservation™ for the orthopedics market,” said NuOrtho Surgical CEO Jeff Morrill. “Dr. McRury brings tremendous experience and expertise to the commercial, clinical, technical and regulatory sides of our business. The reception and enthusiasm we have received from the medical and healthcare communities have helped us attract top talent like this to NuOrtho. These are exciting days as we prepare for our initial launch in the coming months.”

NuOrtho has three primary product platforms for preserving healthy tissue. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. The Bone Fusion technology is revolutionary as it can fuse bone together, and ultimately has the potential to replace screws and plates that are used in many procedures today such as a simple ACL knee procedure. The company has nine issued patents. There are several additional patents pending in the Tissue Preservation™ arena.


January 17, 2010 - What’s Nu? Standard Times

NuOrtho Surgical, Inc., a medical device manufacturer start-up here has patented a surgical probe designed to preserve joint cartilage during orthopedic repair procedures and combat degenerative osteoarthritis of the knees, a problem that plagues millions as they age.

The company is planning to launch this innovative new technology early this year, pending FDA approval.

"This is a very exciting approach. If you can help someone with mid-range osteoarthritis improve their mobility and at the same time preserve the remaining healthy articular cartilage, that is a huge win-win," said Dr. Jeremy Stern, a well-known orthopedic surgeon who practices in the SouthCoast and is a member of NuOrtho's Advisory Panel.

NuOrtho was founded in September, 2008 by Jeffrey W Morrill, CEO, a marketing executive who worked in the medical device arena at Johnson & Johnson for eight years; Roy E. Morgan, a mechanical engineer with expertise in radiofrequency energy who worked at Stryker, Artemis Medical and Abbott Labs, and now serves as chief development officer; and Dr. Wayne K. Augé II, the chief clinical officer and a board-certified orthopedic surgeon. Morgan oversees research and development from California and Dr. Augé is located in New Mexico.

Morgan and Augé began creating a patent portfolio in 2003, and the company now holds nine patents for the tissue preservation technology and eight trademarks.

They put together their first million dollars in start-up financing in March, 2009 and a second million had been secured by November. The company continues to look for strategic partners to help the firm grow.

Osteoarthritis is a widespread problem in the United States, afflicting more than 20 million people — especially baby boomers — a primary market targeted by NuOrtho. According to www.MedicineNet.com, the degenerative condition affects more males before the age of 45. After age 55, it affects more women. Genetics can play a role, and sometimes it affects much younger people. Symptoms of osteoarthritis can include joint pain with activity, limited motion, joint inflammation, morning stiffness and pain at night.

According to the American Academy of Orthopaedic Surgeons' web site, www.aaos.org, the articular cartilage is located between the thigh bone and the shin bone, cushions the knee joint and helps muscles move the knee more efficiently. As the body ages, the cartilage becomes thinner and more vulnerable to fraying and lesions which can limit the gliding ability of the knee joint and severely limit mobility. Eventually, the cartilage breaks down completely, which results in the "bone-on-bone" situation which can require a total knee replacement.

"Once cartilage is gone, it's gone," said Morrill. "The goal of our new surgical probe is to allow the surgeon to preserve the healthy articular cartilage tissue while repairing and contouring the damaged area — using lower temperatures and lower levels of radiofrequency energy — all with the benefit of avoiding necrosis, the killing of healthy tissue."

The company has trademarked its probe, called Ceruleau, which means "blue water" in Latin and French. Like other probes already on the market, it is designed for one-time use while performing a surgical treatment for articular knee cartilage called a chondroplasty — a procedure where the damaged knee joint surface is carefully re-contoured to remove lesions and fraying and improve mobility.

The NuOrtho approach is designed to create a smooth cartilage surface without cutting, shaving or heating tissue to a high degree, all of which can create collateral tissue damage.

"This procedure can be a Catch-22," said Stern. "If you smooth the knee surface completely, you may sacrifice too much cartilage. If you leave it too rough, the knee may still get caught or stuck, which can limit mobility."

Morrill emphasized the careful attention paid to the design details of the probe, based on years of experience in the medical devices arena, combined with feedback from orthopedic surgeons.

"It has been reshaped to better fit the contour of the surgeon's hand as opposed to being stick-like," he commented. "The exterior surface has been texturized for better grip and improved surgical precision and control. And we added the power button to the probe handle itself instead of utilizing a floor pedal which requires additional cabling and more cords in the operating room."

Other benefits Morrill mentioned include enhanced patient recovery and reduced operating time, and lower costs to the surgical facility.

According to Morrill, choosing the SouthCoast for NuOrtho's corporate headquarters was a conscious decision. "We could have been on the river in Cambridge, but we felt the SouthCoast has a lot to offer and there is a strong labor pool available in the area. It's a way for us to ultimately contribute to the economic strength and stability of this region with some potential long-term job creation."

NuOrtho has been incubating at the Advanced Technology Manufacturing Center and currently employs 36 independent contractors or consultants on a full or part-time basis who have been working on developing the new technology and the prototype. When FDA approval comes, the company anticipates hiring about 100 new employees.

"The ATMC is an example of our regional efforts to promote continuing economic development in the SouthCoast area," said Robert A. Mellion, president and CEO of the Fall River Chamber of Commerce & Industry. "That's why NuOrtho's progress is so exciting. It is an innovative company with the potential for great success in the future — and the potential for new jobs in Fall River is always welcome news."

After Ceruleau is launched, the company is planning to adapt the design for use in other areas of the anatomy that typically present with wear and tear issues — shoulders, hips etc., as well as a new meniscal (knee) cartilage repair probe.

NuOrtho's core technology, trademarked Tissue Preservation, is the foundation of the product platform, with multiple future applications planned for soft tissue treatment, including a bone fusion product, which could replace the need for screws, pins or plates in orthopedic procedures.

"It's been an interesting ride," said Morrill. "For the first nine months, we were chasing potential investors, but now that has all changed, and they are chasing us."

--
www.southcoasttoday.com/apps/pbcs.dll/article?AID=/20100117/NEWS/1170333/-1/NEWS06

November 17, 2009 - NuOrtho Surgical secures $1 million in Series B Financing

Fall River, MA, November 17, 2009 — NuOrtho Surgical, Inc., a medical device firm focused on surgical instruments to enable Tissue Preservation™ in the orthopedic arena, announced today it has closed $1 million in Series B financing from private investors and individuals familiar with the orthopedic industry. The company plans to use the capital to file their FDA 510k application on their first product, scale up manufacturing capabilities and procure initial inventory for product launch in the first part of 2010.

“NuOrtho is the type of industry that Fall River is looking for. Projected job growth in the health care and medical manufacturing sector continues to be an area of opportunity for us. As a company that continues to be incubated and grow in the Advanced Technology and Manufacturing Center (ATMC), NuOrtho has a breadth of patented products that will take medical devices to the next level and create jobs for years to come. We look forward to accommodating each stage of growth in Fall River,” states Kenneth Fiola Jr., Executive Vice President of the Fall River Office of Economic Development.

NuOrtho CEO Jeffrey M. Morrill comments, “As the population ages, there is a growing need to sustain long-term mobility, particularly among baby boomers. The future is bright for innovative products that have a clear point of difference and benefits. Our technology leverages a low level Radio Frequency energy to restore mobility in patients by preserving healthy tissue in many procedures done today designed for both soft and hard tissue. While we await FDA approval, we are excited to build our team to commercialize our Tissue Preservation™ platform.”

Mr. Joseph A. Ciffolillo, a proven industry veteran, served in management positions with Boston Scientific Corporation (including Chief Operating Officer), Johnson & Johnson and Codman. Mr. Ciffolillo comments, “I have followed NuOrtho since inception. Their growth strategy and innovative product platforms have tremendous growth potential.”

NuOrtho has three primary product platforms for preserving healthy tissue. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. The Bone Fusion technology is revolutionary as it can fuse bone together, and ultimately has the potential to replace screws and plates that are used in many procedures today (such as a simple ACL knee procedure). The company has added 4 new patents and now has 9 issued patents. There are several additional patents pending in the tissue Preservation™ arena. Their first product has early stage validation testing. The device will contour and smooth articular cartilage that has tears, lesions or is fraying, inhibiting knee mobility.

Company founders, Jeffrey W. Morrill, Dr. Wayne K. Auge II and Roy E. Morgan, have broad medical device experience and proven results of creating and launching new products and technologies (at Johnson & Johnson, as a surgeon and at Stryker respectively).


September 16, 2009 - NuOrtho Surgical Featured at Entrepreneur Forum

Fall River, MA September 16, 2009 - NuOrtho Surgical was the featured speaker at the Southern New England Entrepreneurs Forum (SNEEF) focusing on effective Business Planning at the UMASS Advance Technology and Manufacturing Center. The Forum attracted investors and entrepreneurs from the area to learn about creating and managing Business Plans from NuOrtho and the Panel of funding experts. The panel included moderator Bob Creeden who is Managing Partner of Partners Innovation Fund, Bob Lamkin of Bay Angels, Dan Myer from Pt. Judith Capital and Jeff Morrill from NuOrtho Surgical.

NuOrtho Surgical Inc. showcased their Tissue Preservation™ platform that is focused on the Orthopedic market place. CEO Jeffrey Morrill outlined their three product platforms of Soft Tissue Treatment, Agent Delivery and Bone Fusion and how they have been successful in building their business in a touchy economic climate. The most critical component is having a realistic plan with strategies to focus on. For NuOrtho, that included identifying a starting point from which to commercialize their whole platform building upon soft tissue treatment for cartilage. While there is the game changing capability of Bone Fusion, NuOrtho is establishing a product that will actually be used in their future platforms and will generate revenue sooner with this approach. An educational animation of how the cartilage treatment works can be seen at www.NuOrtho.com.

Dr. Louis Petrovic, the Director of the UMASS Advanced Technology and Manufacturing Center commented, “We are delighted that SNEEF showcased one of our more exciting Tech Venture Center companies. NuOrtho is doing innovative, creative, and exciting work that we expect will make it economically successful and that we believe will lead to jobs for U.MASS Dartmouth students and South Coast residents.

Morrill stated the Forum was productive in several ways including initiating conversations with strategic partners, investors and potential employees. We also recognized how much we have accomplished in one year as we shared our story including two additional issued patents bringing the total for NuOrtho to 9 – a great accomplishment for a start up. A big part of our success is the ability to operate in a strategic incubator like the ATMC. We would not be where we are without them.


July 7, 2009 - NuOrtho Surgical Featured at Medtec Investor Conference

Fall River, MA; July 7, 2009 - NuOrtho Surgical was a featured speaker at the recent Medtec Insights IN3 investor conference in Boston. The conference is the largest East Coast Strategic Partnership and Investment Meeting for Medical Technology Executives.

NuOrtho Surgical Inc. showcased their Tissue Preservation platform that is focused on the Orthopedic Surgeon marketplace. CEO Jeffrey Morrill outlined their point of entry product for soft tissue debridement and contouring. The technology has tremendous potential and is the foundation for their patented game changing technology for Bone Fusion. The potential to fuse bone together instead of using plates and screws has broad applications in the orthopedic marketplace and beyond. This opens up the ability to go beyond just bone fillers and grafts.

Morrill stated the conference was productive in opening up strategic conversations with existing ortho players as well as some looking to enter the space.


June, 2009 - USPO Issues Seventh Patent to NuOrtho Surgical

The USPTO has issued a new patent to NuOrtho Surgical, their seventh issued patent. NuOrtho is a developer of surgical instruments that enable Tissue Preservation in the Medical arena. The company will help doctors be more effective and efficient in their soft and hard tissue procedures minimizing collateral damage. The company is headquartered in Massachusetts.

The patent is titled “Electrosurgery Devices”. The specific patent application extends the low energy RF foundation already established by NuOrtho for treating tissue within the body. Treatment options enabled by the new approach include therapeutic devices to effect advantageous tissue changes and enhance the overall healing response of tissues.

NuOrtho’s product portfolio in development includes instruments for debridement and contouring of soft tissue. One key application will be for articular cartilage in the knee. As people age and cartilage frays or basic activity cause tears, NuOrtho’s probe can smooth and contour tissue to help patients return to pain free mobility. A game changing product is their bone fusing technology for hard tissue. This has the potential to eliminate the use of some plates and screws in basic procedures in orthopedics, Cranial Maxilla Facial and even the Veterinary arena.

Dr. Brant Bair, Chair of NuOrtho’s advisory panel sees tremendous potential for NuOrtho’s product portfolio. As an active tri-athlete and Orthopedic surgeon, he sees the benefits of Tissue Preservation for active people and the aging population. “The technology has the ability to advance the science of Orthopedic surgery and the team is laser focused on getting the first product to market.”

NuOrtho is focused on the US marketplace for initial launch. They will expand into the EU with partners. The company has recently opened a Series B round for strategic partners.


February 12, 2009 - NuOrtho Surgical Completes Initial Tissue Testing

NuOrtho Surgical announced today that it has successfully completed tissue testing with its first device. "I have used the device and it exceded all performance expectations", says Brant A. Bair, MD, an orthopedic surgeon and NuOrtho Advisory Panel Chairman.


January 15, 2009 - M2D2 Supports NuOrtho Surgical

The Massachusetts Medical Device Development Center (M2D2), a medical device support team located at UMASS Lowell and Worchester is doing their part in helping rebuild our economy by supporting the innovative technology of NuOrtho Surgical. The M2D2 program develops and facilitates early stage medical device companies to ensure their success in New England. Dr. Jeremy Stern, a leading orthopedic surgeon on the South Coast, comments that NuOrtho's cartilage probe's ability to treat cartilage without causing side effects (like necrosis--killing of healthy tissue) has tremendous commercial application. It would be the holy grail." NuOrtho has raised initial funds to build their cartilage probe and is looking for help as they shift from the R&D to the commercialization phase. The initial funding has come from surgeons and device industry people who see the need and value the product has for patients. Dr. Stern:"NuOrtho has a broad list of patented products that will enable them to be the next great orthopedic company in Massachusetts."


January 14, 2009 - NuOrtho Surgical and BC Tech Announce Partnership

BC Tech: "NuOrtho Surgical is a medical device start up focused on Tissue Preservation for Orthopedic surgeons and their patients. Their innovative technology leverages a low level of Radio Frequency energy to restore mobility in patients by preserving healthy tissue during surgical procedures. We're proud NuOrtho Surgical selected BC Tech to assist in commercializing this therapy and look forward to a successful product launch."


Recent Updates